Annual EBITDA
-$300.29 M
+$20.95 M+6.52%
December 31, 2023
Summary
- As of February 7, 2025, ALLO annual EBITDA is -$300.29 million, with the most recent change of +$20.95 million (+6.52%) on December 31, 2023.
- During the last 3 years, ALLO annual EBITDA has fallen by -$49.64 million (-19.80%).
- ALLO annual EBITDA is now -76.92% below its all-time high of -$169.74 million, reached on December 31, 2021.
Performance
ALLO EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$62.99 M
-$188.00 K-0.30%
September 30, 2024
Summary
- As of February 7, 2025, ALLO quarterly EBITDA is -$62.99 million, with the most recent change of -$188.00 thousand (-0.30%) on September 30, 2024.
- Over the past year, ALLO quarterly EBITDA has dropped by -$4.27 million (-7.27%).
- ALLO quarterly EBITDA is now -1158.77% below its all-time high of $5.95 million, reached on December 31, 2021.
Performance
ALLO Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$261.26 M
-$4.27 M-1.66%
September 30, 2024
Summary
- As of February 7, 2025, ALLO TTM EBITDA is -$261.26 million, with the most recent change of -$4.27 million (-1.66%) on September 30, 2024.
- Over the past year, ALLO TTM EBITDA has increased by +$63.33 million (+19.51%).
- ALLO TTM EBITDA is now -9960.11% below its all-time high of -$2.60 million, reached on March 31, 2018.
Performance
ALLO TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ALLO EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +6.5% | -7.3% | +19.5% |
| 3 y3 years | -19.8% | +13.6% | -19.5% |
| 5 y5 years | -45.2% | -17.3% | -32.6% |
ALLO EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -76.9% | +6.5% | -1158.8% | +34.1% | -53.9% | +24.2% |
| 5 y | 5-year | -76.9% | +6.5% | -1158.8% | +34.1% | -53.9% | +24.2% |
| alltime | all time | -76.9% | +6.5% | -1158.8% | +53.2% | -9960.1% | +24.2% |
Allogene Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$62.99 M(+0.3%) | -$261.26 M(+1.7%) |
| Jun 2024 | - | -$62.80 M(-4.8%) | -$256.99 M(-5.2%) |
| Mar 2024 | - | -$65.95 M(-5.1%) | -$271.09 M(-9.9%) |
| Dec 2023 | -$300.29 M(-6.5%) | -$69.53 M(+18.4%) | -$300.73 M(-7.4%) |
| Sep 2023 | - | -$58.72 M(-23.6%) | -$324.59 M(-5.8%) |
| Jun 2023 | - | -$76.90 M(-19.6%) | -$344.50 M(+1.2%) |
| Mar 2023 | - | -$95.58 M(+2.3%) | -$340.53 M(+6.0%) |
| Dec 2022 | -$321.24 M(+89.3%) | -$93.39 M(+18.8%) | -$321.24 M(+44.8%) |
| Sep 2022 | - | -$78.63 M(+7.8%) | -$221.90 M(+1.5%) |
| Jun 2022 | - | -$72.92 M(-4.4%) | -$218.61 M(+1.8%) |
| Mar 2022 | - | -$76.30 M(-1382.6%) | -$214.76 M(+26.5%) |
| Dec 2021 | -$169.74 M | $5.95 M(-107.9%) | -$169.74 M(-30.2%) |
| Sep 2021 | - | -$75.34 M(+9.1%) | -$243.21 M(+3.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$69.06 M(+120.8%) | -$234.10 M(+3.4%) |
| Mar 2021 | - | -$31.28 M(-53.7%) | -$226.30 M(-9.7%) |
| Dec 2020 | -$250.66 M(+27.2%) | -$67.52 M(+1.9%) | -$250.66 M(+2.0%) |
| Sep 2020 | - | -$66.23 M(+8.1%) | -$245.86 M(+5.4%) |
| Jun 2020 | - | -$61.27 M(+10.1%) | -$233.31 M(+7.6%) |
| Mar 2020 | - | -$55.64 M(-11.3%) | -$216.85 M(+10.1%) |
| Dec 2019 | -$196.98 M(-4.7%) | -$62.72 M(+16.8%) | -$196.98 M(+19.9%) |
| Sep 2019 | - | -$53.68 M(+19.8%) | -$164.34 M(+9.3%) |
| Jun 2019 | - | -$44.81 M(+25.3%) | -$150.29 M(-37.4%) |
| Mar 2019 | - | -$35.77 M(+18.9%) | -$240.04 M(+16.0%) |
| Dec 2018 | -$206.76 M | -$30.08 M(-24.1%) | -$206.87 M(+17.0%) |
| Sep 2018 | - | -$39.64 M(-70.5%) | -$176.79 M(+28.9%) |
| Jun 2018 | - | -$134.56 M(+5081.4%) | -$137.16 M(+5181.4%) |
| Mar 2018 | - | -$2.60 M | -$2.60 M |
FAQ
- What is Allogene Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Allogene Therapeutics?
- What is Allogene Therapeutics annual EBITDA year-on-year change?
- What is Allogene Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Allogene Therapeutics?
- What is Allogene Therapeutics quarterly EBITDA year-on-year change?
- What is Allogene Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Allogene Therapeutics?
- What is Allogene Therapeutics TTM EBITDA year-on-year change?
What is Allogene Therapeutics annual EBITDA?
The current annual EBITDA of ALLO is -$300.29 M
What is the all time high annual EBITDA for Allogene Therapeutics?
Allogene Therapeutics all-time high annual EBITDA is -$169.74 M
What is Allogene Therapeutics annual EBITDA year-on-year change?
Over the past year, ALLO annual EBITDA has changed by +$20.95 M (+6.52%)
What is Allogene Therapeutics quarterly EBITDA?
The current quarterly EBITDA of ALLO is -$62.99 M
What is the all time high quarterly EBITDA for Allogene Therapeutics?
Allogene Therapeutics all-time high quarterly EBITDA is $5.95 M
What is Allogene Therapeutics quarterly EBITDA year-on-year change?
Over the past year, ALLO quarterly EBITDA has changed by -$4.27 M (-7.27%)
What is Allogene Therapeutics TTM EBITDA?
The current TTM EBITDA of ALLO is -$261.26 M
What is the all time high TTM EBITDA for Allogene Therapeutics?
Allogene Therapeutics all-time high TTM EBITDA is -$2.60 M
What is Allogene Therapeutics TTM EBITDA year-on-year change?
Over the past year, ALLO TTM EBITDA has changed by +$63.33 M (+19.51%)